151. Identification of a novel compound that inhibits osteoclastogenesis by suppressing nucleoside transporters.
- Author
-
Katsuyama S, Sugino K, Sasazawa Y, Nakano Y, Aono H, Morishita K, Kawatani M, Umezawa K, Osada H, and Simizu S
- Subjects
- Animals, Cell Line, Tumor, Female, Gene Expression Regulation drug effects, Humans, Mice, Mice, Inbred ICR, Osteoclasts drug effects, Osteogenesis genetics, RANK Ligand pharmacology, RAW 264.7 Cells, Signal Transduction drug effects, Small Molecule Libraries chemistry, Tritium metabolism, Nucleoside Transport Proteins metabolism, Osteoclasts metabolism, Osteogenesis drug effects, Small Molecule Libraries pharmacology
- Abstract
We screened small-molecule compounds that inhibit osteoclast differentiation to find new anti-osteoporosis agents and found that a novel compound, SUKU-1, suppressed osteoclastogenesis. We also synthesized 38 derivatives of SUKU-1 and discovered that nine of them had inhibitory effects on osteoclastogenesis and that SUKU-33 was the most potent inhibitor. Next, we investigated the mechanisms by which SUKU-33 suppressed osteoclast differentiation. By measuring the uptake of [(3) H]-uridine in cells, we found that SUKU-33 suppressed both equilibrative nucleoside transporters and concentrative nucleoside transporters. These results suggest that SUKU-33 inhibits osteoclast differentiation by suppressing nucleoside transporters., (© 2016 Federation of European Biochemical Societies.)
- Published
- 2016
- Full Text
- View/download PDF